Dechert (New York)

Sophie Mitouard

Dechert (New York)
Lawyer (Associate)

Sophie Mitouard focuses her practice on antitrust and competition matters, with particular emphasis on public law and litigation before administrative courts. Ms. Mitouard has significant experience in the filing of merger notifications to the Commission and to several European Competition Authorities in the automotive, food and health sector. She has also participated in summary proceedings regarding public contracts in the health sector, as well as drafted memos regarding the practices of dominant operators in a regulated sector. Prior to joining Dechert, Ms. Mitouard trained in the competition and public departments of French law firms and in the legal department of an airline. Sophie is admitted in Paris only. She is not admitted in New York.

Linked authors

Dechert (New York)
Dechert (Paris)
Dechert (Paris)
Dechert (Moscow)
Dechert (Philadelphia)

Articles

1249 Bulletin

Mélanie Thill-Tayara, Marion Provost, Sophie Mitouard Dominance in the pharmaceutical sector: An overview of EU and national case law

1118

In a communication of November 2020, the European Commission presented its ‘new Pharmaceutical Strategy for Europe’, the main objective of which is to achieve a strong, fair, competitive, and green pharmaceutical industry, centered on patients’ needs. The Commission’s ambition is to remove existing barriers that prevent patients’ access to innovative and affordable medicines, while facilitating the digital transformation of the industry. In this context, the enforcement of competition rules certainly remains an important instrument for the Commission to achieve its goals and we expect the sector to remain a key priority throughout the European Union. Just in the past year, several important decisions have been adopted and multiple investigations opened, both in antitrust and merger control.

Mélanie Thill-Tayara, Marion Provost, Sophie Mitouard The Paris Court of Appeal upholds the decision of the Competition Authority to fine a pharma company for abuse of dominance (Jansson-Cilag / Johnson & Johnson)

131

More particularly, the Court affirmed the FCA’s conclusion that Janssen infringed competition law by, on the one hand, disparaging competing fentanyl specialties towards health professionals, emphasizing the risks associated with a switch from Durogesic© to a generic version and, on the other (...)

Books

Send a message